Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000491695 | SCV000579605 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-09-15 | criteria provided, single submitter | clinical testing | The c.2356-4G>A intronic variant results from a G to A substitution 4 nucleotides upstream from coding exon 21 in the TSC2 gene. This nucleotide position is poorly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Invitae | RCV001080449 | SCV000765996 | likely benign | Tuberous sclerosis 2 | 2023-12-19 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000838626 | SCV000980500 | likely benign | not provided | 2019-11-20 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001080449 | SCV002039648 | likely benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003932796 | SCV004749335 | likely benign | TSC2-related condition | 2023-04-20 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |